TABLE 1

Pre-operative characteristics

Parameters before PEATotal (n=92)Patients without residual PH after PEA (n=56)Patients with residual PH after PEA (n=36)
Age at PEA (years)63 (range 17–79)58 (range 18–79)63 (range 17–79)
Women41 (45%)24 (43%)17 (47%)
BMI (kg·m−2)26.7 (24.3–30.1)26.7 (23.8–30.1)26.5 (25.0–30.0)
Use of PH-specific medication before PEA27 (29%)13 (23%)14 (39%)
NYHA class I/II/III/IV (%)2/38/52/84/37/48/110/38/59/3
6MWD (m)412±108, n=67413±112, n=39411±105, n=28
NT-proBNP (ng·L−1)507 (132–1646)326 (115–1250)932 (224–2748)
Comorbidities
 Ischaemic heart disease3 (3%)0 (0%)3 (8%)
 Obstructive lung disease12 (13%)6 (11%)6 (17%)
 Diabetes mellitus8 (9%)5 (9%)3 (8%)
 Systemic hypertension35 (38%)18 (32%)17 (47%)
 Malignancy6 (7%)4 (7%)2 (6%)
 Thyroid disease7 (8%)3 (5%)4 (11%)

Data are presented as mean±sd, median (interquartile range) or n (%) unless otherwise stated. 6MWD: 6-min walk distance; BMI: body mass index; NT-proBNP: N-terminal pro-brain natriuretic peptide; NYHA: New York Heart Association; PEA: pulmonary endarterectomy; PH: pulmonary hypertension.